SCHEMBL17000015

SCHEMBL17000015

CNC(=O)c1cc(Oc2ccc(C(C)NC(=O)Nc3ccc(C)c(C)c3)cc2)ccn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 11/20 0.56
EPHX2 P34913 4/20 0.56
KDR P35968 8/20 0.55
MAPK14 Q16539 5/20 0.55
RET P07949 4/20 0.55
AURKB Q96GD4 3/20 0.55
ABL1 P00519 3/20 0.55
EPHA2 P29317 3/20 0.55
MAP3K20 Q9NYL2 3/20 0.55
PLK4 O00444 2/20 0.55
AURKA O14965 2/20 0.55
MAPK13 O15264 2/20 0.55
MAP4K4 O95819 2/20 0.55
LCK P06239 2/20 0.55
FYN P06241 2/20 0.55
LYN P07948 2/20 0.55
SRC P12931 2/20 0.55
RPS6KB1 P23443 2/20 0.55
AXL P30530 2/20 0.55
FRK P42685 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15573188 0.92 RAF1 (0.58) RAF1EPHX2KDRMAPK14RET
SCHEMBL15573129 0.88 RAF1 (0.62) RAF1EPHX2KDRMAPK14RET
SCHEMBL13603827 0.87 KDR (0.60) RAF1EPHX2KDRMAPK14RET
SCHEMBL170976 0.83 RAF1 (0.80) RAF1EPHX2KDRMAPK14RET
SCHEMBL171259 0.83 RAF1 (0.80) RAF1EPHX2KDRMAPK14RET
SCHEMBL14422931 0.82 RAF1 (0.60) RAF1EPHX2KDRMAPK14RET
SCHEMBL15573239 0.81 RAF1 (0.52) RAF1EPHX2KDRMAPK14RET
SCHEMBL257980 0.80 RAF1 (0.82) RAF1EPHX2KDRMAPK14RET
SCHEMBL6014811 0.80 KDR (0.63) RAF1EPHX2KDRMAPK14RET
SCHEMBL17000014 0.80 LMNA (0.62) RAF1EPHX2KDRMAPK14RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS DDR2, DDR1, DDRGK1 RAF1 3072/4885EPHX2 3657/4885KDR 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.